Poland Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims to integrate pharmacoecomonics to ensure Poland can find an efficient balance between innovative and generic treatments for long-term stability. Furthermore,…
Tunisia Mohamed Khalil Tamim, Alcon’s head of regulatory affairs Africa manages the regulatory affairs of 47 countries in Alcon’s African cluster. He explains the necessity of creating and harmonizing medical device-specific regulatory frameworks in Africa for the benefit of patients, and documents Alcon’s strategy to navigate a price-sensitive market despite its…
Ukraine Ukraine’s bold decision to outsource public procurement of medicines to international agencies to combat rampant corruption has been well received by the pharma MNCs operational in the country, but faces criticism from domestic players. “Healthcare procurement was widely considered as one of the areas most seriously altered by corruption” Tetiana…
Canada Newly appointed minister of health of Canada, The Honourable Ginette Petitpas Taylor, shares the core tenets of her mandate, the Federal government’s priorities for investment into the Canadian healthcare ecosystem, as well as the strategic significance of the life sciences industry for the country. Healthcare was a core issue on…
Poland Wojciech Kuta, editor-in-chief of Rynek Zdrowia, a leading Polish healthcare publication, discusses the interacting dynamics of the obstacles facing Polish healthcare, as the country aims to increase healthcare spending to six percent of GDP by 2025. Furthermore, he highlights the inefficient sectors of the system, moves to promote innovation and…
Poland Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and highlights the obstacles that the generics ecosystem faces in light of the new reimbursement act. Furthermore, he provides insights into…
Bulgaria Gergana Semova and Petko Konakchiev, founders of PharmDedict, share an overview of the Bulgarian regulatory dynamism, the reasons why healthcare companies should continue investing in the country, and explain why PharmDedict is not only a service provider, but also a solutions provider. After having worked for several years in the…
Bulgaria Olia Vassileva, executive director at the Bulgarian Association of Pharmaceutical Wholesalers (BAPW), gives a clear explanation of the challenges facing wholesalers in Bulgaria, its current as well as future role in the healthcare system, and its true commitment towards patient safety. As an introduction, please briefly explain the main activities…
Tunisia Habib Toumi, CEO of the Tunisian National Social Security Fund (CNSS), discusses implementing universal healthcare coverage, restoring the financial equilibrium of the fund, and managing the continuous improvement of services provided in the CNSS policlinics. Can you describe the operational characteristics of the Tunisian National Social Security Fund (CNSS)? “Concerning…
India At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based pharmaceutical companies in India, putting the patient at the center of all that they do is part of their DNA. On the occasion of their 51st Annual Day celebrations, experts met to discuss the need to…
Bulgaria Prof. Dr. Kamen Plochev, Dr. M. Sc., recently appointed as the governor of the National Health Insurance Fund in Bulgaria, discusses the key issues he has identified for the Bulgarian healthcare system as well as how he intends to tackle them and ultimately establish a more efficient and transparent organization.…
India Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges of the current pricing climate, and the ultimate goal of providing affordable and accessible medicines to the nation’s roughly 1.3…
See our Cookie Privacy Policy Here